PEAR-GLIO

Indication: Primary brain tumour

Location: United Kingdom (see below for sites)

Type: Observational

ClinicalTrials information - in process

Protocol - please note, this may not be the most recent version - do not use at trial sites

Background:

Brain tumours are the leading cause of cancer death in the under-40s, and are one of the least researched cancers.

Although there are a number of different drugs, and combinations of drugs, which can be used, we have no way of predicting who will respond to which drugs. This means that some people receive drugs that they don’t respond to.

Description:

This observational study is recruiting up to 50 patients with primary brain tumours who are undergoing surgery. Patients will have surgery as planned, and donate a 40ml blood sample. We will use excess tissue from the operation (which would otherwise go to waste), along with the blood sample, to explore the effect of different drugs on the tumour. This tumour will be used for analysis on Pear’s system to determine the likelihood of response to a given treatment regimen.

As this is an observational study, the results will not be shared with your oncologist at the time of initial treatment, and you will be treated using the standard of care. The goal of the study is to establish the accuracy of Pear’s test at predicting response to treatment to help guide future patients to better treatments.

If you are interested in enrolling, please contact your doctor about whether you are eligible.

For more information, contact trials@pearbio.com

Open Sites & Investigators:

The lead site is Imperial College Healthcare NHS Trust.

We hope to open this trial in early 2024